Consensus of the Austrian society for gynecology and obstetrics/gynecologic oncology working group;Konsensus der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG)/Arbeitsgemeinschaft für Gynäkologische Onkologie

Geburtshilfe und Frauenheilkunde

Volumn 69, Issue 12, 2009, Pages 1071-1077

  Petru, E ^a   Wildt, L ^b   Stummvoll, W ^c   Singer, C ^d   Speiser, P ^d   Fischerlehner, G ^c   Reitsamer, R ^e   Kubista, E ^d   Marth, C ^b   Winter, R ^f   Menzel, C ^e   Leodolter, S ^d   Seifert, M ^d   Zervomanolakis, I ^b   Zeimet, A ^b   Reinthaller, A ^d  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Abteilung für Spezielle Gynäkologie   (Austria)

^f Geburtshilflich Gynakologische Universitats Klinik   (Austria)

Author keywords

Breast cancer; Chemotherapy; Consensus; Contraception; Fertility; GnRH analogues; Hormone replacement therapy; Oncologic diseases; Ovarian reserve

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; BLEOMYCIN; BUSULFAN; CETUXIMAB; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DESOGESTREL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; INHIBIN; IRINOTECAN; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; MUELLERIAN INHIBITING FACTOR; NORETHISTERONE; OXALIPLATIN; PREDNISOLONE; TAMOXIFEN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

AGING; AUSTRIA; BIOCHEMISTRY; BREAST CANCER; CANCER PATIENT; CHEMOTHERAPY; CONFERENCE PAPER; CONSENSUS; CONTRACEPTION; ENDOMETRIUM CARCINOMA; FEMALE; FERTILITY; FERTILIZATION IN VITRO; GERM CELL; HODGKIN DISEASE; HORMONE SUBSTITUTION; HUMAN; INFERTILITY THERAPY; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; OVARIAN FUNCTION TEST; OVARIAN RESERVE; OVARY FOLLICLE; OVULATION INHIBITION; PREGNANCY;

EID: 73949140459     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0029-1240642     Document Type: Conference Paper

References (35)

1. Barakat R, Bundy B, Spirtos N et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I and II endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 2006 24 587-592
2. Behringer K, Breuer K, Reineke T et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's lymphoma study group. J Clin Oncol 2005 23 7555-7564
3. Beiner M, Covens A. Surgery insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer. Nat Clin Pract Oncol 2007 4 353-361
4. Blumenfeld Z, Avivi I, Linn S et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996 11 1620-1626
5. Blumenfeld Z, Avivi I, Eckman A. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin's lymphoma. Fertil Steril 2008 89 166-173
6. Brewer M, Gershenson D, Herzog C et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999 17 2670-2675
7. Bundred N, Kenemans P, Beckmann M et al. Effect of tibolone on breast cancer recurrence: Liberate trial bone sub-study. Cancer Res 2009 69 (Suppl.) 79s
8. Familiari G, Caggiati A, Nottola S et al. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod 1993 8 2080-2087
9. Gershenson D, Miller A, Champion V et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: A Gynecologic Oncology Group study. J Clin Oncol 2007 25 2792-2797
10. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer is it safe?), a randomised comparison: trial stopped. Lancet 2004 363 453-455 (Pubitemid 38210063)
11. Holmberg L, Iversen O, Rudenstam C et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008 100 475-482
12. Kendall A, Dowsett M, Folkerd E et al. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006 17 584-587
13. Kenemans P, Bundred N, Foidart J M. et al. Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol Published online January 23, 2009 Published online January 23, 2009[nl]
14. Lee S, Schover L, Partridge A et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006 24 1-11
15. Levgur M. Estrogen and combined hormone therapy for women after genital malignancies: A review. J Reprod Med 2004 49 837-848
16. Mattle V, Behringer K, Engert A et al. Female fertility after cytotoxic therapy protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol 2005 66 (Suppl.) 77-82
17. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001 7 535-543
18. Meirow D, Rabinovici J, Katz D et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006 107 1634-1641
19. Morice P, Leblanc E, Rey A et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC and SFOG. Hum Reprod 2005 20 1379-1385
20. Perez G, Knudson C, Leykin et al. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997 3 1228-1232
21. Plante M, Renaud M, Gregoire J et al. Outcome of 81 pregnancies following radical trachelectomy for the treatment of early-stage cervical cancer. Gynecol Oncol 2008 108 S32
22. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987 26 169-177
23. Randall T, Kurman R. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997 90 434-440
24. Schilder J, Thompson A, DePriest P et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002 87 1-7
25. Shepherd J, Spencer C, Herod J et al. Radical vaginal trachelectomy as a fertilty-sparing procedure in women with early-stage cervical cancer-cumulative pregnancy rate in a series of 123 women. Brit J Obstet Gynecol 2006 113 719-724
26. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004 10 251-266
27. Stillman R, Schinfeld J, Schiff I et al. Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol 1981 139 62-66
28. Tilly J. Oocyte apoptosis: prevention strategies, and implications for female aging and the menopause. Ann Endocrinol 2003 64 82-84
29. Trinh X B., Tjalma W, Makar A et al. Use of levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 2008 91 17-22
30. Williams S, Blessing J, Liao S et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology group. J Clin Oncol 1994 12 701-706
31. Ushijima K, Yahata H, Yoshikawa H et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007 25 2798-2803
32. Zanetta G, Chiari S, Rota et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1997 104 1030-1035
33. Zanetta G, Rota S, Chiari S et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001 19 2658-2664
34. Zanetta G, Bonazzi C, Cantu M et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001 19 1015-1020
35. Zervomanolakis I, Hofer S, Mattle V et al. Kinderwunsch nach Chemotherapie wissenschaftliche Perspektiven und klinische Anwendung. J Gynäkol Endokrinol 2008 18 7-13